Harvard Bioscience(US:HBIO)2025-08-11 12:00Financial Performance - Q2 2025 revenue was $20.5 million, compared to $23.1 million in Q2 2024[6] - Gross margin in Q2 2025 was 56.4%, compared to 57.2% in Q2 2024[6] - Adjusted EBITDA for Q2 2025 was $1.5 million, compared to $1.3 million in Q2 2024[6] - Q3 2025 revenue is projected to be in the range of $19 million to $21 million[16] - Q3 2025 gross margin is projected to be in the range of 56% to 58%[16] Regional Performance - APAC region experienced a 25.4% year-over-year decrease in Q2 2025, but with a 1.1% increase from F/X[7] - EMEA region was relatively flat, with a 0.3% year-over-year decrease in Q2 2025, but with a 5.0% increase from F/X[7] - US Pre-Clinical declined 11.7% year-over-year in Q2 2025[7] Strategic Focus - The company is prioritizing stabilizing the core business and restructuring the balance sheet to build sustainable sales and profitability[19] - The company is positioning the business for renewed growth and margin expansion in 2026 and beyond[19] - The company is focused on accelerating product adoption by leveraging a strong and innovative pipeline[19]